Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.50 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.50 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK7 | Q13164 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16759847 | 1.00 | ENPP2 (0.50) | ENPP2DGAT2ATXN2HRH3MAPK8 | |
| SCHEMBL16962301 | 0.94 | ENPP2 (0.56) | ENPP2DGAT2ATXN2HRH3MAPK8 | |
| SCHEMBL21323007 | 0.94 | ENPP2 (0.56) | ENPP2DGAT2ATXN2HRH3MAPK8 | |
| SCHEMBL16962303 | 0.94 | ENPP2 (0.56) | ENPP2DGAT2ATXN2HRH3MAPK8 | |
| SCHEMBL17310935 | 0.89 | ENPP2 (0.53) | ENPP2DGAT2ATXN2HRH3HTR2B | |
| SCHEMBL16963420 | 0.89 | ENPP2 (0.53) | ENPP2DGAT2ATXN2HRH3HTR2B | |
| SCHEMBL17310934 | 0.89 | ENPP2 (0.53) | ENPP2DGAT2ATXN2HRH3HTR2B | |
| SCHEMBL22911027 | 0.88 | ENPP2 (0.56) | ENPP2DGAT2ATXN2HRH3MAPK8 | |
| SCHEMBL16759797 | 0.88 | ENPP2 (0.56) | ENPP2DGAT2ATXN2HRH3MAPK8 | |
| SCHEMBL16963706 | 0.87 | ENPP2 (0.50) | ENPP2DGAT2ATXN2MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | ENPP2 2448/4885DGAT2 3760/4885ATXN2 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.